[Pilot study of the action of Doqualast on dietary hyperuricemia in volunteers].
For eight days 8 healthy volunteers were treated with a formula diet and additional 1680 purine base per day. Beginning with day 5, doqualast was administered orally in a dosage of 200 mg t.i.d. Serum uric acid level was lowered by doqualast from 7.84 +/- 0.9 mg/dl to 5.09 +/- 0.8 mg/dl (p less than 0.01). Uric acid clearance increased from 7.6 +/- 2.5 ml/min to 11.5 +/- 2.4 ml/min (p less than 0.05). Excretion of uric acid in urine increased from 622 +/- 231 mg/d to 890 +/- 233 mg/d at the end of therapy. Total cholesterol in serum was lowered from 222 +/- 70 mg/dl to 159 +/- 48 mg/dl (p less than 0.05). The new uric acid lowering drug doqualast was well tolerated clinically. No adverse effects on biochemistry parameters were observed.
Matzkies
F
F
Kurparkklinik, Bad Neustadt/Saale und Boehringer Ingelheim KG, Abteilung Medizin, Ingelheim, Rhein.
Stechert
R
R
Rauber
G
G
Matzkies
F
F
Drescher
U
U
D000328:Adult; D002784:Cholesterol / Q000097:blood; D004032:Diet; D005526:Food, Formulated; D006634:Histamine H1 Antagonists / Q000009:adverse effects / Q000494:pharmacology*; D006801:Humans; D008297:Male; D010865:Pilot Projects; D011799:Quinazolines / Q000009:adverse effects / Q000494:pharmacology*; D014527:Uric Acid / Q000097:blood*
D006634:Histamine H1 Antagonists; D011799:Quinazolines; D014527:Uric Acid; D002784:Cholesterol; C051309:doqualast
Pilotstudie zur Wirkung von Doqualast bei diätetisch erzeugter Hyperurikämie an Probanden.